Respiratory failure & ventilation
Nebulized Heparin in Adults With Acute Respiratory Failure: A Meta-Analysis of Randomized Trials
Pooled result · Ten studies includedResult — go to the resultRelative risk 0.79 95% CI 0.66–0.95Authors' conclusion
Nebulized unfractionated heparin may improve survival in patients with respiratory failure without increasing adverse events.
Study context
- Population
- Adults with respiratory failure, invasively mechanically ventilated or not16 studies
- Participants
- 787 vs 833
- Comparison
- Nebulized unfractionated heparin vs standard care or placebo
- Nebulized heparinn = 787
- Controln = 833reference
- Outcome
- All-cause mortality
- Follow-up
- Longest
Methodological detailsrandom-effects
- Random-effects
Pooled result
Ten studies included
Relative risk
0.79
95% CI 0.66–0.95
Events by group
Nebulized heparin vs Control
RR 0.79 (95% CI 0.66–0.95)
As reported in the abstract
Further pooled results
| Outcome | Mean difference (95% CI) |
|---|---|
| Ventilation-free days · day 28 | +4.85 (1.47–8.24) |
Safety
- No minor bleeding or heparin-induced thrombocytopenia reported
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Nebulized Heparin in Adults With Acute Respiratory Failure: A Meta-Analysis of Randomized Trials. Crit Care Med. Published 18 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →